This is a guest blog by Tim Turnham, PhD, Executive Director, The Melanoma Research Foundation.
When the Melanoma Research Foundation (MRF) decided to hold a gala event in Philadelphia, we knew immediately that we wanted to honor GSK as part of that evening.
The MRF is the largest and oldest nonprofit dedicated to melanoma. We were started by and for patients and our grassroots approach enables us to retain that close connection. Five years ago, we expanded our Wings of Hope for Melanoma gala program. These events are not formal, black-tie dinners, but rather, a reflection of our roots—warm, interactive, focused on patients and others who have been affected personally by melanoma. Choosing the right honoree is critical to retaining that atmosphere.
GSK was a natural choice for our Philadelphia event. First of all, the company has made a major commitment to the City of Philadelphia. GSK recently moved into a new state-of-the art facility in Philadelphia’s historic Navy Yard. This location was largely abandoned in the late 1990’s. The City changed the facility into a mixed-use business core. GSK’s decision to move to a 205,000 square foot facility there helps secure the future of this once stagnant part of the city.
Second, GSK’s decision to utilize an environmentally friendly design reflects a corporate culture focused on sustainability and responsibility. The new building is double-LEED Platinum certified and incorporates many features designed to create a safe and healthy work environment.
Most significantly, however, GSK has also made a major commitment to fighting melanoma, the deadliest skin cancer.
The MRF was pleased to be able to recognize the contributions GSK has made as a good corporate citizen and as a champion in the fight against melanoma by presenting the company, as represented by Dr. Paolo Paoletti, President of Oncology, GSK with the Vision of Hope Award at the first annual Wings of Hope Philadelphia. For photos of the event, click here.